par Berghmans, Thierry
Référence Revue des Maladies Respiratoires Actualites, 12, 2, page (2S359-2S365)
Publication Publié, 2020-12-01
Article révisé par les pairs
Résumé : In 2020, immunotherapy, alone or in combination with conventional chemotherapy, is the reference treatment for non-small cell lung cancer without oncogenic driver mutation consist. A new concept of oligometastatic disease emerged during those last years, suggesting that integrating a local ablative therapy with a systemic one could modify the course of the neoplastic disease. Pre-clinical data are showing a synergistic effect between immunotherapy (antiPD1/PDL1 or antiCTLA4) and radiotherapy, strong rationale for considering combination of both treatments in oligometastatic cancer. Into clinic, data, yet if clinically meaningful, remain preliminary. Numerous prospective trials, randomised or not, are underway and should answer this question in the next few years. © 2020 SPLF. Published by Elsevier Masson SAS. All rights reserved.